Verona Pharma plc Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q4 FY2019 As of Dec 31, 2019
Goodwill
Intangible assets
Property, plant and equipment
Right-of-use assets
Total non-current assets
Prepayments and other receivables
Current tax receivable
Short term investments
Cash and cash equivalents
Total current assets
Total assets
Share capital
Share premium
Share-based payment reserve
Accumulated loss
Total equity
Derivative financial instrument
Lease liability
Trade and other payables
Total current liabilities
Assumed contingent liability
Non-current lease liability
Deferred income
Total non-current liabilities
Total equity and liabilities
ASSETS
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Prepaid expenses
Tax incentive receivable
Contract asset
Equity interest receivable
Other current assets
Total current assets

Non-current assets:
Furniture and equipment, net
Inventory, long-term
Goodwill
Equity interest
Right-of-use assets
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Royalties payable
Revenue interest purchase security agreement
Current operating lease liabilities
Warrants
Taxes payable
Other current liabilities
Total current liabilities
Non-current liabilities:
Term loan
Revenue interest purchase security agreement
Non-current operating lease liabilities
Total non-current liabilities
Total liabilities
Shareholders' equity:
Ordinary £0.05 par value shares; 703,189,462 and 703,189,462 issued, and 687,930,486 and 677,008,254 outstanding, at June 30, 2025 and December 31, 2024, respectively
Additional paid-in capital
Ordinary shares held in treasury
Accumulated other comprehensive loss
Accumulated deficit
Total shareholders' equity
Total liabilities and shareholders' equity

Comments